Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Main Markets Strong But Compliance Issues Linger

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

India_moneybox_1200x675
Dr Reddy’s Posted A Surprise Loss In Its Financial Third Quarter • Source: Shutterstock

Dr Reddy's Laboratories, India’s second-largest drug company, plunged unexpectedly into the red in its financial thid quarter, hit by a $156.5m write-off related to its generic version of the NuvaRing (etonorgestrel/ethinyl estradiol) contraceptive. But a strong underlying performance, reflecting a string of US launches and a tight rein on costs, propelled the company’s shares to a 52-week high.

The company, which has been grappling with US regulatory compliance issues and falling product prices in the US, crashed to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business